How it works:
Cladribine is a purine nucleoside analogue that selectively targets lymphocytes. It interferes with DNA and RNA synthesis, resulting in tumour cell death. It is particularly effective in slowly progressing leukaemias and lymphomas.
Recommended for:
The drug is administered as an intravenous infusion in a hospital setting. The dose is determined individually based on the patient’s weight and diagnosis. It must be diluted in a compatible infusion solution before use.
Side effects
